Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00976521 · ClinicalTrials.gov registry record · NA
The INFUSE - Anterior Myocardial Infarction (AMI) Study
A NA study, sponsored by Atrium Medical Corporation.
- Completed
- Registry status
- NA
- Development phase
- 452
- Enrollment target
NCT00976521: Completed NA study, sponsored by Atrium Medical Corporation.
NCT00976521 is a NA study that has completed, run by Atrium Medical Corporation. The registered enrollment target is 452 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00976521, a NA study, has completed, sponsored by Atrium Medical Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 452 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, controlled, single-blind, randomized study with up to 452 subjects enrolled in up to 50 US and European sites. Subjects who present with anterior ST-elevation myocardial infarction (STEMI) and an occluded proximal or mid left anterior descending (LAD) with TIMI 0/1/2 flow will be eligible for randomization to one of the following arms: 1. Local infusion of abciximab following thrombus aspiration 2. Local infusion of abciximab and no thrombus aspiration 3. No local infusion and thrombus aspiration 4. No local infusion and no thrombus aspiration In addition, a cardiac magnetic resonance imaging (MRI) sub-study evaluating microvascular obstruction (MVO) will be performed with up to 160 subjects at up to 20 sites.
Primary Outcome
The primary endpoint of the INFUSE AMI study is infarct size as a percentage of total left ventricular mass at 30 days as measured by cardiac MRI (cMRI), comparing the pooled randomized active (abciximab) infusion to the pooled non infusion arms, without regard to aspiration.
Interventions
- DRUG Abciximab local infusion
- OTHER No local infusion
- PROCEDURE Thrombus aspiration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 452 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-04 |
| Phase | NA |
What the finished NCT00976521 record still lists
NCT00976521 is an interventional study that assigns participants to a tested intervention. The registered 452 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 3 interventions - of which Abciximab local infusion is the first listed.
NCT00976521 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00976521 about?
NCT00976521 is a clinical study titled "The INFUSE - Anterior Myocardial Infarction (AMI) Study". This is a multicenter, open-label, controlled, single-blind, randomized study with up to 452 subjects enrolled in up to 50 US and European sites. Subjects who present with anterior ST-elevation myocardial infarction (STEMI) and an occluded proximal or mid left anterior descending (LAD) with TIMI 0/1...
What is the current status of trial NCT00976521?
This trial is currently completed. It is a NA study. The enrollment target is 452 participants. The study started on 2009-09. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00976521?
The interventions under investigation include: Abciximab local infusion (DRUG), No local infusion (OTHER), Thrombus aspiration (PROCEDURE).
Who is sponsoring clinical trial NCT00976521?
This trial is sponsored by Atrium Medical Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00976521's enrollment target sits among peer trials
452 225th of 2000 higher than 1,776 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05676255 · 452 participants · Phase 2
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
- NCT05703178 · 452 participants · Phase 3
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
- NCT03460977 · 453 participants · Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- NCT04708171 · 453 participants
The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia